Found: 4
Select item for more details and to access through your institution.
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
- Published in:
- Journal of Investigative Medicine High Impact Case Reports, 2022, p. 1, doi. 10.1177/23247096221129470
- By:
- Publication type:
- Article
Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00345
- By:
- Publication type:
- Article
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
- Published in:
- Journal of Investigative Medicine High Impact Case Reports, 2022, v. 10, p. 1, doi. 10.1177/23247096221129470
- By:
- Publication type:
- Article
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
- Published in:
- Current Oncology, 2023, v. 30, n. 7, p. 6432, doi. 10.3390/curroncol30070473
- By:
- Publication type:
- Article